Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) have earned a consensus rating of “Hold” from the eleven brokerages that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $10.50.

Several research analysts recently commented on the stock. Oppenheimer reaffirmed a “hold” rating on shares of Synergy Pharmaceuticals in a research note on Thursday, March 1st. Zacks Investment Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 1st. BidaskClub downgraded shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, February 6th. CIBC reissued a “market perform” rating on shares of Synergy Pharmaceuticals in a research report on Friday, January 5th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Synergy Pharmaceuticals in a research report on Thursday, February 1st.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ SGYP traded down $0.01 during mid-day trading on Wednesday, hitting $1.80. The stock had a trading volume of 546,094 shares, compared to its average volume of 5,489,437. The company has a quick ratio of 3.88, a current ratio of 4.33 and a debt-to-equity ratio of -21.05. Synergy Pharmaceuticals has a 1 year low of $1.68 and a 1 year high of $4.84. The company has a market cap of $446.45, a price-to-earnings ratio of -1.75 and a beta of 1.17.

Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. Synergy Pharmaceuticals had a negative net margin of 1,333.76% and a negative return on equity of 652.66%. The company had revenue of $9.40 million for the quarter, compared to the consensus estimate of $7.12 million. Synergy Pharmaceuticals’s revenue was up 840.0% on a year-over-year basis. equities research analysts anticipate that Synergy Pharmaceuticals will post -0.52 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of SGYP. HBK Sorce Advisory LLC purchased a new position in Synergy Pharmaceuticals during the 4th quarter valued at $103,000. Sandy Spring Bank purchased a new position in Synergy Pharmaceuticals during the 4th quarter valued at $109,000. MetLife Investment Advisors LLC purchased a new position in Synergy Pharmaceuticals during the 4th quarter valued at $124,000. Lehman Financial Resources Inc. increased its position in Synergy Pharmaceuticals by 405.9% during the 4th quarter. Lehman Financial Resources Inc. now owns 68,300 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 54,800 shares during the period. Finally, Teacher Retirement System of Texas increased its position in Synergy Pharmaceuticals by 354.8% during the 4th quarter. Teacher Retirement System of Texas now owns 83,552 shares of the biopharmaceutical company’s stock valued at $186,000 after purchasing an additional 65,182 shares during the period. 53.08% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Synergy Pharmaceuticals (SGYP) Receives $10.50 Consensus PT from Brokerages” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/04/16/synergy-pharmaceuticals-sgyp-receives-10-50-consensus-pt-from-brokerages.html.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Analyst Recommendations for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.